3D Medicines Inc.
Climate Impact & Sustainability Data (2022, 2023)
Reporting Period: 2022
Environmental Metrics
Total Carbon Emissions:3,746.82 tCO2e/year
Scope 1 Emissions:3,087.61 tCO2e/year
Scope 2 Emissions:659.21 tCO2e/year
Carbon Intensity:0.07 tCO2e/RMB 10,000 of revenue
ESG Focus Areas
- Product liability
- Environmental protection
- Social welfare
- Corporate governance
- Innovative R&D
- Responsible operation
- People first
Environmental Achievements
- Reduced greenhouse gas emission intensity to 0.07 t CO2e/RMB 10,000 of revenue
- Reduced energy consumption intensity to 20.00 kWh/RMB 10,000 of revenue
- Reduced water consumption intensity to 0.19 m3/RMB 10,000 of revenue
- No major environmental protection issues or environmental penalties
Social Achievements
- Envafolimab® available in 1,000 hospitals and 1,000 pharmacies in over 200 cities across 30 provinces in China, benefiting over 20,000 patients.
- RMB 53.3 million in charitable contributions.
- Established the “3DMed Education Charity Fund” and donated RMB 400,000 to 20 poverty-stricken students.
- Zero working days lost due to work-related injuries and zero deaths due to work-related injuries.
Governance Achievements
- Established and improved a complete ESG management system.
- No corruption litigation cases.
- No information leakage events.
- No anti-fraud complaints.
Climate Goals & Targets
Long-term Goals:
- Continue to protect the environment, set environmental goals, and cultivate the green office concept of all employees.
Medium-term Goals:
- Actively improve the product launch speed and product liability management.
Short-term Goals:
- Further establish and improve the Company's existing ESG management system.
Environmental Challenges
- Market risks related to increasing market attention on environmental products and services.
- Technical risks related to increased costs of equipment upgrades and weakened competitiveness.
- Acute physical risks from extreme climate events and natural disasters.
- Chronic physical risks from long-term effects of climate change.
- Reputation risks related to meeting public expectations for low-carbon transformation.
Mitigation Strategies
- Established a green supply chain system.
- Actively carried out technological innovation and R&D.
- Established an emergency response mechanism.
- Strengthened monitoring and early warning of climate change.
- Made corresponding plans to reduce carbon emissions and enhance communication with stakeholders.
Supply Chain Management
Supplier Audits: 82 suppliers audited in 2022
Responsible Procurement
- Compliance, transparency and diversification procurement mode.
Climate-Related Risks & Opportunities
Physical Risks
- Extreme climate events, natural disasters, environmental accidents
Transition Risks
- Stricter government policies and regulations
Reporting Standards
Frameworks Used: Appendix 27 Environmental, Social and Governance Reporting Guide to the Guide for Main Board Securities Listing Rules issued by the Stock Exchange of Hong Kong Limited
Awards & Recognition
- 2022 "GuruClub Golden Award · Annual Most Valuable IPO Enterprise"
- 2022 "Golden Wisdom Award · Award for Excellence in Pharmaceutical and Biological Industry"
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:412.85 tCO₂e (indirect)
Scope 2 Emissions:412.85 tCO₂e
Total Energy Consumption:723,926 kWh
Water Consumption:2,769.20 m3
Waste Generated:43.71 tons (hazardous)
Carbon Intensity:0.07 tCO₂e/RMB 1 million revenue
ESG Focus Areas
- Environmental Management
- Employee Well-being
- Corporate Governance
- R&D Innovation
- Supply Chain Management
- Community Engagement
Environmental Achievements
- Total electricity consumption decreased by 36.20% year-on-year.
- All R&D centers meet local emission standards.
- Zero major environmental problems or penalties in 2023.
Social Achievements
- Provided over 20,000 drugs to cancer patients through patient assistance projects.
- 17 employees received job promotions.
- Zero lost workdays due to work-related injuries in 2023.
- Conducted one-on-one interviews and surveys to assess employee satisfaction.
Governance Achievements
- Established a comprehensive R&D management system.
- Improved patent application approval process.
- Implemented anti-corruption training for employees.
- Established a whistle-blowing mechanism.
Climate Goals & Targets
Environmental Challenges
- Government policy changes related to climate change.
- Potential negative public perception due to insufficient climate action.
- Climate change impacts on energy prices and production costs.
- Emergence of new technological standards due to climate change.
- Acute and chronic physical risks from climate events.
Mitigation Strategies
- Monitoring climate change policies and establishing a compliance system.
- Reducing carbon emissions and improving energy efficiency.
- Strengthening market monitoring and supply chain management.
- Investing in technological research and innovation.
- Establishing emergency response mechanisms and flexible supply chains.
Supply Chain Management
Supplier Audits: Annual audits for 295 suppliers
Responsible Procurement
- Compliance, transparency, and diversification in procurement.
- Supplier qualification audits considering environmental and social impact.
Climate-Related Risks & Opportunities
Physical Risks
- Extreme climate events, natural disasters, environmental accidents
Transition Risks
- Policy and regulatory changes, market demand shifts
Reporting Standards
Frameworks Used: Appendix 27 Environmental, Social, and Governance Reporting Guide to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
Awards & Recognition
- "Outstanding Big Health Enterprise of the Year"
- "Excellent Case of ESG Pioneer Practitioner"
- "Top Ten Tumor Black Technologies of the Year"
- "High-growth Enterprise of the Year"
- "Top 100 Chinese Pharmaceutical Innovation Enterprises"
- "Top 20 Listed Companies in Chinese Pharmaceutical Industry with ESG Competitiveness"